Moderna Stock Price, News & Analysis

Moderna, Inc. (Nasdaq: MRNA) will host a live conference call and webcast on August 5, 2021, at 8:00 a.m. ET to discuss its second quarter 2021 financial results and provide a corporate update. To participate, call 866-922-5184 (domestic) or 409-937-8950 (international) with conference ID 5749439. The call will also be available via webcast on Moderna's investor website. Since its inception, Moderna has shifted to a leading biotechnology company with a diverse vaccine and therapeutics portfolio, particularly recognized for its COVID-19 vaccine.

Moderna, Inc. (Nasdaq: MRNA) announced a supply agreement with the government of Argentina for 20 million doses of its COVID-19 vaccine, including potential updated variant boosters, slated for delivery starting Q1 2022. CEO Stéphane Bancel highlighted the company’s commitment to global vaccine availability. Moderna has received emergency use authorization for its vaccine in over 50 countries and is advancing multiple programs across infectious diseases and other therapeutic areas, showcasing robust manufacturing capabilities and ongoing clinical trials.

Moderna (Nasdaq: MRNA) has initiated the Phase 1/2 study of its mRNA-1010 vaccine, targeting seasonal influenza. The study involves approximately 180 healthy adults aged 18 and older in the U.S. The quadrivalent vaccine aims to protect against significant influenza lineages as recommended by WHO. This is Moderna's first seasonal influenza vaccine candidate entering clinical trials, marking a significant step in its mRNA vaccine strategy. The company envisions developing combination vaccines for multiple respiratory viruses, aiming to enhance public health response.

Moderna (Nasdaq: MRNA) has commenced the manufacturing of its COVID-19 vaccine at Recipharm’s Monts site in France, following the European Medicines Agency's approval on June 11, 2021. This collaboration aims to bolster vaccine production capacity in Europe, essential for ongoing vaccination efforts. Moderna's recent investments are set to double drug substance manufacturing across Europe and enhance safety stock of raw materials. The COVID-19 Vaccine Moderna has received marketing authorization in 49 countries and is integral to Moderna's strategic growth in mRNA therapeutics.

Moderna (Nasdaq: MRNA) has received authorization from the government of India for its COVID-19 vaccine for emergency use in adults aged 18 and older. This marks a significant milestone in the global fight against the pandemic. The vaccine is already authorized in over 50 countries and has received Emergency Use Listing from the WHO. Moderna, recognized for its rapid development capabilities, continues to expand its mRNA platform with ongoing development programs across various therapeutic areas.

Moderna (Nasdaq: MRNA) announced new findings from in vitro studies showing that its COVID-19 Vaccine effectively produces neutralizing titers against various SARS-CoV-2 variants. Vaccination elicited neutralization against all tested variants, including Beta, Delta, and others. Although some variants showed reduced antibody response, overall effectiveness remains promising. Moderna is actively studying new variants and developing a multivalent booster candidate. The mRNA platform continues to support vaccine development initiatives to combat evolving strains of the virus.

Moderna (NASDAQ: MRNA) announces that Kate Cronin will join as Chief Brand Officer on July 12, 2021. She will be part of the Executive Committee, reporting to CEO Stéphane Bancel. Cronin, previously Global CEO at Ogilvy Health, brings extensive experience in brand strategy and marketing in the biopharmaceutical sector. She aims to enhance Moderna's brand and communicate its potential in mRNA therapeutics. Moderna continues to evolve, with a diverse pipeline and a strong commitment to advancing mRNA science in vaccines and therapeutics.

Moderna, Inc. (Nasdaq: MRNA) announced the European Commission's purchase of an additional 150 million doses of its COVID-19 vaccine, raising total commitments to 460 million doses. Deliveries of the updated vaccine are set to begin in 2022, pending regulatory approval. Initial Phase 2 study data revealed that a 50 µg booster dose significantly increased neutralizing antibodies against SARS-CoV-2 variants. Moderna continues to meet its EU delivery commitments for 2021, supported by its mRNA platform and expanded manufacturing capabilities.

Moderna (Nasdaq: MRNA) has significantly expanded its workforce in Massachusetts, increasing from approximately 830 to 1,500 employees between March 2020 and March 2021. The company has created over 650 new jobs at its Norwood manufacturing facility. Moderna received a tax incentive from the Massachusetts Life Sciences Center for its commitment to employ 155 new full-time staff until 2025. A recent expansion in Norwood will boost Moderna's COVID-19 vaccine production capacity by 50%, aiming for up to 3 billion doses by 2022.